Abbreviations used in this paper: ANOVA = analysis of variance; DMSO = dimethyl sulfoxide; FITC = fluorescein isothiocyanate; FGF = fibroblast growth factor; FGFR = FGF receptor; PDGF = platelet-derived growth factor; PDGFR = PDGF receptor; SD = standard deviation; VEGF = vascular endothelial growth factor; VEGFR = VEGF receptor. D represents one example of a potent polyvalent inhibitor of angiogenic signaling pathways because it targets VEGFR, FGFR, and PDGFR. Cocrystal structure analyses have shown that SU6668 binds to the catalytic domains of these receptors and interrupts signaling following ligand binding. 11 Furthermore, SU6668 has been shown to inhibit phosphorylation and, thereby, activity of VEGFRs and PDGFRs in a dose-and time-dependent manner in vivo. 10 By doing this, SU6668 not only prevents tumor angiogenesis but also provides a potent antivascular efficacy, resulting in regression of selected experimental tumor types. 10 Recently, we studied the effects of SU6668 on the angiogenesis, perfusion, and growth of experimental malignant gliomas by using intravital multifluorescence videomicroscopy. We were able to show that SU6668 exerts more potent antiangiogenic and antivascular activities than a selective VEGFR inhibitor, resulting in the failure of tumor perfusion, inadequate tumor oxygenation, and suppression of tumor growth. 3 Nevertheless, the drawback of our proof-of-concept studies was that we studied the effect of SU6668 in a subcutaneous (ectopic) malignant glioma model. It remains unclear whether SU6668 is also effective in treating malignant gliomas that are growing in an orthotopic microenvironment and whether the agent is potent enough to affect survival when the tumor is growing intracerebrally.
The aim of the present study, therefore, was to assess the effect of SU6668 on the angiogenesis, microcirculation, and growth of malignant gliomas in an orthotopic tumor model. To achieve this we implanted malignant C6 glioma cells in a long-term cranial window preparation in nude mice and examined tumor vascularization and growth by performing intravital multifluorescence videomicroscopy. In addition, we implanted malignant C6 glioma cells intracerebrally by stereotactic means and assessed the effect of SU6668 on animal survival.
Materials and Methods

Cells and Cell Cultures
We cultured C6 rat glioma cells in HAM F-10 culture medium in 12-well dishes at 37˚C in a humidified atmosphere of 5% CO 2 /95% air. Two days after preparation of the cranial window, the coverslip was temporarily removed and a suspension of C6 cells (2.5 ϫ 10 5 tumor cells in 1.5 l phosphate-buffered saline) was implanted. 23 
Animals Used for the Study
The experiments were performed in athymic, adult nude mice (nu/nu; weight range 28-32 g) that had been bred and maintained in a specific pathogen-free environment. All experiments were approved by the animal care and use committees of the local government authorities.
Intravital Multifluorescence Videomicroscopic Studies
As implantation sites for the C6 glioma cells, we used the the cerebral cortex made manifest by the long-term cranial window. 23 The microsurgical techniques for the preparation of the cranial window have been previously described in detail. 24 Briefly, animals were anesthetized by a subcutaneous injection of 7.5 mg of ketamine hydrochloride and 2.5 mg of xylazine per 100 mg of body weight. The head of each animal was fixed in a rodent stereotactic frame (David Kopf Instruments, Tujunga, CA). The skin on top of the frontal and parietal skull was cut, and the underlying periosteum was scraped off to the temporal crests. Using an electrical high-speed drill with a burr tip size of 0.5 mm, a circular bone flap (0.7-1 cm in diameter) was created and freed from the underlying dura mater and the sagittal sinus with the aid of a modified microdissector. The dura was removed with the aid of iris microscissors, avoiding any damage to the sinus and bridging veins. Finally the window was sealed with a glass coverslip, which was affixed to the bone by using histocompatible glue.
Intravital multifluorescence videomicroscopy (epiillumination) was performed using a modified Axiotech Vario microscope with a blue (450-490 nm) and green (520-570 nm) filter block. 26 Observations were made using ϫ 3.2 (short distance), ϫ 10 (long distance), and ϫ 20 (water immersion) working objectives (all from Zeiss, Oberkochen, Germany), resulting in magnifications of 50, 200, and 400, respectively. The malignant glioma cells and the tumor microvasculature were made visible by means of a low-light-level chargecoupled device video camera (CF8/1 FMC; Kappa, Gleichen, Germany). Microscopic images were recorded using an S-VHS video system (Panasonic, Munich, Germany) for offline analysis. Fast-blue labeling of the C6 cells allowed for the precise identification of individual tumor cells when blue-light epiillumination was applied. 26 By using contrast enhancement with 2% FITC-conjugated dextran (0.1 ml of FITC-dextran-150 administered intravenously via the tail vein; MW 150,000; Sigma Chemical Co., St. Louis, MO) and bluelight epiillumination, we were able to observe angiogenic sprouts, individual microvessels, and, finally, the glioma microvasculature. 26 To study the effects of SU6668 on the angiogenesis, perfusion, and growth of malignant gliomas, the mice were treated with SU6668 (SUGEN, Inc., San Francisco, CA) following two different experimental protocols. In Protocol 1 treatment with SU6668 (75 mg/kg/day in 50 l of DMSO, administered intraperitoneally to five animals) was started on the day of glioma cell implantation, reflecting the immediate treatment of tumors at the time of their implantation. In Protocol 2 SU6668 treatment was started in five mice on Day 6 after glioma cell implantation, reflecting the treatment of already vascularized and progressing tumors. Control mice received the vehicle alone (50 l DMSO, administered intraperitoneally to five animals for Protocol 1 and four animals for Protocol 2).
Intravital multifluorescence videomicroscopy was performed on Days 3, 6, 10, and 14 after cell implantation. To standardize repeated intravital microscopy of the heterogeneous glioma microvasculature, the tumor mass and peritumoral tissue were divided into three radial zones (peritumoral, marginal, and central) at high magnification. On each day, the newly formed microvasculature was investigated individually within these distinct zones, resulting in six to nine measurements per animal for each observed time point. 3 To assess the extent of tumor vessel regression, identical microvascular regions were compared before treatment was initiated and afterward throughout the entire study period. A quantitative analysis of intravital microscopic observations was performed with the aid of a computer-assisted image analysis system. 26 Tumor growth was assessed by measurement of the tissue area (mm 2 ) covered by the fluorescent solid tumor mass. An analysis of microcirculatory parameters included the total tumor vascular density (cm Ϫ1 ), which was defined as the length of all newly formed microvessels per area of interest and observed time point, the functional vascular density (cm Ϫ1 ), which was defined as the length of microvessels perfused with red blood cells per area of interest, and the diameters of perfused tumor blood vessels (m). The mean microvascular diameters per region of interest were determined by averaging the values of between five and 10 microvessels. To assess the permeability of the vessels, we compared intravascular and extravascular fluorescence intensities of multiple individual tumor microvessels in both peritumoral and intratumoral areas, and calculated a permeability index according to the following equation: permeability index = intravascular fluorescence/extravascular fluorescence. 26 
Stereotactic Glioma Cell Implantation for Survival Experiments
To assess the effect of SU6668 on survival following orthotopic tumor implantation, C6 cells were implanted into the brain of nude mice by stereotactic means. The heads of the mice were fixed in a stereotactic rodent head holder. Implantation was performed by in-jecting 5 ϫ 10 5 cells stereotactically into the right striatum. The animals were divided into three groups (A, B, and C) and treatment was initiated on Day 6 after implantation: Group A (10 mice) received vehicle alone (DMSO 50 l/day, administered intraperitoneally), Group B (six mice) received an intraperitoneal injection of 100 mg/ kg SU6668 in 50 l DMSO every 3 days (low dose), and Group C (eight mice) received an intraperitoneal injection of 75 mg/kg in 50 l DMSO every day (high dose). The animals were killed as soon as one exhibited neurological deficits or had lost more than 30% of their initial body weight. Survival was analyzed by applying Kaplan-Meier survival curves for the three experimental groups.
Histological Findings
At the end of the in vivo experiments, the animals were killed and the tumor-bearing brains were excised and processed for histological analysis. The specimens were fixed with 10% paraformaldehyde and embedded in paraffin. Three-micrometer sections were stained with H & E. To assess tumor blood-vessel density, we performed immunohistochemical staining for the endothelial cell-specific marker CD31/PECAM. Five-micrometer sections were incubated with rabbit or goat serum, followed by an incubation with a rat anti-mouse antibody against CD31/PECAM (Mec13.3). 23 The primary antibody was diluted in goat serum supplemented with 20% mouse serum. Secondary antibodies were applied using Vectastain kits (Vector Laboratories, Burlingame, CA). Finally, the tissue sections were incubated with avidin-biotin horseradish-peroxidase complex and 3-amino-9-ethylcarbazole substrate, developed, and counterstained with hematoxylin.
Statistical Analysis
Quantitative data are expressed as mean values Ϯ SDs. The mean values of the microcirculatory data were calculated from mean values in each animal. For an analysis of differences between groups, the post hoc unpaired Bonferroni t-test was used following a oneway ANOVA. Results in which the probability was less than 0.05 when compared with values in control animals were considered significant. Survival data are presented in Kaplan-Meier survival curves. For an analysis of differences in survival, the log rank test was used.
Results
Antiangiogenic Effect of SU6668 During Vascular Initiation
In control tumors, the first signs of malignant glioma angiogenesis were observed by Day 3 after implantation (Fig.  1A) . These signs included the formation of microvascular sprouts and sinusoidal vessel configurations originating from cerebral capillaries and postcapillary venules. The newly formed microvessels subsequently branched and interconnected, forming initial, red blood cell-perfused microvascular networks. By Day 10, the area of the glioma mass was completely vascularized (Fig. 1B) . The microvasculature was characterized by a dense network of tumor blood vessels and a heterogeneous and chaotic angioarchitecture ( Fig. 1B and C) . In contrast, tumors treated with SU6668 from the time of their implantation displayed a markedly suppressed tumor angiogenic activity compared with controls. During the entire observation period, the microvasculature of SU6668-treated tumors was characterized by a retarded network of tumor blood vessels, most of which were not perfused ( Fig. 1D-F) .
The quantitative analysis of the total vascular density confirmed reduced angiogenic activity during SU6668 treatment. As illustrated in Fig. 2A , daily treatment of tumors resulted in a significantly reduced total vessel density throughout the 14-day observation period. This suppressed angiogenic activity translated into significantly impaired tumor perfusion, as indicated by the 70% reduction in functional vessel density (Fig. 2B) . The SU6668 not only reduced the number of perfused vessels, but also negatively affected the diameter of functional tumor vessels, especially at the end of the observation period ( tumor compartments further revealed that it was more pronounced in peripheral areas than in the center of the tumor, that is, in regions where the highest angiogenic activity within the tumor microvasculature could be observed. In contrast to the inhibitory effect of SU6668 on tumor angiogenesis and tumor perfusion, a quantitative analysis of tumor vessel permeability revealed no significant difference between treated and control tumors (permeability index on Day 14 [mean Ϯ SD]: 1.12 Ϯ 0.18 in control tumors and 1.12 Ϯ 0.03 in SU6668-treated lesions-not a statistically significant difference). As a consequence of these microvascular changes, glioma growth was markedly suppressed. This was confirmed by the planimetric analysis of tumor growth, which revealed a 52% growth inhibition following daily treatment with SU6668 when begun at the vascular initiation phase (Fig. 2D) . The histological analysis of tumors at the end of the observation period confirmed the antitumor activity of SU6668. As illustrated in Fig. 3 , tumor volume and the related mass effect on the adjacent brain were markedly reduced in SU6668-treated tumors compared with control lesions (Fig. 3A-D) . In addition, the immunohistochemical analysis involving the endothelial cellspecific marker CD31/PECAM confirmed the reduction in tumor blood vessel density in SU6668-treated tumors (Fig.  3E-F) .
Antivascular Effect of SU6668 on Established Tumor Blood Vessels
So far we have shown that SU6668 inhibits angiogenesis in gliomas when administered at the time of tumor initiation. Next, we addressed the effects of SU6668 on an already established tumor microvasculature. For this purpose
FIG. 2. Graphs showing the results of a quantitative analysis of total vessel density (A), functional vessel density (B), diameter of perfused blood vessels (C), and tumor growth (D).
Values are represented as means Ϯ SDs. Statistical analysis was performed using ANOVA followed by the post hoc unpaired Bonferroni t-test. *p Ͻ 0.05, **p Ͻ 0.01 compared with control.
FIG. 3. Photomicrographs. A-D: Cryosections of C6 cranial tumors treated with DMSO (A and C) or SU6668 (B and D). H & E (A-D). E and F:
Immunohistochemical staining for the endothelial cell-specific marker CD31/PECAM to visualize tumor blood vessels. Tumors were explanted on Day 14 after implantation into the cortex revealed by the cranial window. Original magnifications ϫ 25 (A and B) and ϫ 200 (C-F).
SU6668 treatment was begun 6 days after tumor implantation; that is, at a time when tumors had already established their microvasculature and had reached an average size of 20 mm 2 . As demonstrated by sequential intravital microscopic studies of identical microvascular regions of interest, SU6668 not only inhibited angiogenesis, but also induced a massive regression of already existing tumor blood vessels ( Fig. 4A and B) . This antivascular activity of SU6668 was confirmed by the quantitative analysis of total and functional vessel densities ( Fig. 4C and E) . Within 4 days of therapy, SU6668 induced vessel regression by 44%, resulting in a significant failure of tumor vessel perfusion. This perfusion failure was further aggravated by the effect of SU6668 on tumor vessel diameters, which failed to enlarge any further during tumor growth after initiation of therapy (Fig. 4D) . Interestingly, however, SU6668-induced vessel regression was not accompanied by an increase in tumor blood vessel permeability and cerebral edema formation, as judged by the extravasation kinetics of the fluorescent tracer (permeability index on Day 10 [mean Ϯ SD]: 1.07 Ϯ 0.03 in control tumors and 1.10 Ϯ 0.05 in SU6668-treated lesions-not a statistically significant difference). Parallel to the microvascular changes, tumor growth persisted after initiation of SU6668 treatment, resulting in a size difference of 40% at the end of the observation period (Fig. 4F) .
Effect of SU6668 on Animal Survival
After we demonstrated that SU6668 exerts antiangiogenic and antivascular effects on an orthotopic malignant glioma model, we finally addressed the question of whether SU6668 also has a relevant impact on animal survival following intracerebral tumor implantation. To test this, animals were treated following two distinct SU6668 dosing regimens (a low dose of 100 mg/kg every 3 days and a high dose of 75 mg/kg daily), starting from Day 7 after implantation. The animals were killed as soon as they exhibited neurological deficits or lost more than 30% of their initial body weight. As illustrated by the time course of the animals' body weights as well as by the Kaplan-Meier survival curves in Fig. 5 , SU6668 prolonged survival in treated animals. The median survival time was increased from 8 days to 15 days (p Ͻ 0.001) in the low-dose group and 18 days (p Ͻ 0.001) in the high-dose group. Nevertheless, a statistical analysis of the survival curves failed to demonstrate a significant difference between the two treatment groups, indicating a lack of dose dependency within this range of dosing.
Discussion
Receptor tyrosine kinases have become an attractive target for pharmacological antitumor therapies during the past decade. 21 Consequently, different small molecules have been developed, which now target individual or multiple receptor tyrosine kinases. At present, several of these inhibitors are under investigation in preclinical trials, whereas others will advance to Phase II and III trials in the near future. Among those, SU6668 represents a member of a novel family of polyvalent inhibitors that target multiple receptor tyrosine kinases implicated in glioma angiogenesis, such as VEGFR-2, PDGFR-␤ and FGFR-1. 6 In previous studies we have demonstrated a potent antiangiogenic and antivascular
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Inhibition of VEGF-PDGF signaling in an orthotopic glioma efficacy for SU6668 in an ectopic malignant glioma model and we have been able to shed some light on the mechanisms of action of this kind of antiangiogenic compound. 3, 11 The principal novel finding of the present study is that SU6668 exerts both its antiangiogenic and antivascular effects in an orthotopic malignant glioma model. Furthermore, we have demonstrated that targeting multiple angiogenic receptor tyrosine kinases using SU6668 results in a significant prolongation of survival following orthotopic tumor implantation.
The C6 malignant glioma model has been extensively characterized with respect to tumor angiogenesis and tumor microcirculation. Recent studies have shown that the C6 malignant glioma is highly angiogenic and that its growth depends on the formation of new tumor blood vessels. 15, 23 Following orthotopic implantation, C6 malignant glioma cells induce vascularization via a sprouting angiogenesis within a few days and establish a functional microvasculature within 1 week after their implantation. 23 Expression analyses have shown that C6 malignant glioma angiogenesis is primarly mediated by VEGF, which is expressed by the tumor cells and activates VEGFR-2 on the endothelial cells of host and tumor blood vessels. Simultaneously, in a coordinate fashion with VEGFR-2 expression, Ang-2 is upregulated by activated host and tumor endothelial cells, rendering the blood vessels in a state of proangiogenic plasticity and VEGF responsiveness. 23 At the same time, Ang-1 expression is 11-fold lower than VEGF expression. 3 To assess the dynamic process of C6 malignant glioma growth, angiogenesis, and microcirculation in detail we observed the tumors via a long-term cranial window by performing intravital multifluorescence videomicroscopy. As previously shown, this experimental approach is advantageous over classic postmortem histological analyses in that it allows for a noninvasive and repetitive identification of individual glioma cells as well as the growing tumor mass, visualization of individual glioma microvessels, and a quantitative analysis of different microcirculatory parameters for a time period of up to 14 days. 4, 24, 27 We elected to study the effects of SU6668 on glioma growth and angiogenesis following two different protocols. First, we treated malignant gliomas immediately after their implantation. Following this protocol, SU6668 caused a significant suppression of glioma angiogenesis, reduced glioma perfusion, and suppressed glioma growth. Second, we treated malignant gliomas in a delayed fashion to assess the effects of SU6668 not only on the formation of new glioma blood vessels but also on already established ones. This protocol also corresponds to the more relevant clinical situation in which therapy is aimed at a newly diagnosed, already established malignant glioma or postoperative residua of malignant glioma. Interestingly, treatment of these established tumors not only inhibited tumor angiogenesis, but also induced a massive regression of already existing tumor blood vessels, an effect that was unexpected for a purely antiangiogenic compound. For example, our previous studies have shown that selective targeting of VEGFR-2 (for example, by SU5416) confers a similar antiangiogenic effect, but does not force established tumor vessels into regression. 3 This indicates that the antivascular effect of SU6668 is attributable to its polyvalent target profile.
Vascular endothelial growth factor has been shown to act not only as an angiogenic factor, but also as a survival factor for endothelial cells and newly formed blood vessels. 1 In vitro studies have demonstrated that VEGF mediates this survival function for endothelial cells through VEGFR-2 and its downstream signal transduction pathways. 5 Recently, however, we have shown that the susceptibility of established glioma blood vessels to an interference with VEGF-VEGFR-2 signaling may be restricted to a fraction of immature vessels, whereas the majority of established glioma blood vessels seems to be resistant to this interference. This resistance is conferred by pericytes, which initially stabilize matured vessels, are secondarily recruited to immature vessels on therapy, and compensatorily express alternative endothelial cell survival factors (for example, Ang-1). 3 Although the detailed molecular basis of how pericytes confer vessel stabilization remains unknown, PDGF-BB-PDGFR-␤ signaling seems to be detrimental for an adequate pericyte-endothelial cell assembly. Thus, the application of polyvalent tyrosine kinase inhibitors, such as SU6668, which selectively block not only VEGFRs but also PDGFR-␤ and, thereby, simultaneously target endothelial cells and pericytes, may act as a potent antivascular strategy, inducing endothelial cell apoptosis, tumor vessel destabilization and regression, and, finally, tumor hypoxia.
FIG. 5. Graphs showing the body weights of the animals (A)
and Kaplan-Meier survival curves (B) for the three experimental groups: controls (10 mice), low-dose SU6668 (100 mg/kg in 50 l DMSO every 3 days; six mice), and high-dose SU6668 (75 mg/kg in 50 l DMSO daily; eight mice). Tumors were implanted stereotactically into the brains of the animals. Treatment was initiated on Day 7 after implantation. Animals were killed when they exhibited neurological deficits or lost more than 30% of their initial body weight.
It is important to note that the extended target profile of SU6668 is neither associated with an increase in drug-related side effects nor negatively affects physiological blood vessels. 3, 11 In line with this, our present intravital microscopic analyses have demonstrated that, in contrast to the glioma vasculature, the integrity and function of cerebral blood vessels remained unaffected by treatment with SU6668. This can be explained on the one hand by fundamental differences between the tumor and normal blood vessels. Accordingly, previous studies have shown that in contrast to normal blood vessels, pericytes of tumor vessels are only loosely associated with endothelial cells, therefore potentially failing to provide vessel maturation. 3, 16 On the other hand, it has been shown that tumor vessels and normal blood vessels are characterized by different gene expression patterns, indicating a distinct target profile when considering antiangiogenic therapies. 22 Initially, we believed that the acute and rapid destabilization of glioma blood vessels may be an important caveat to using similar polyvalent inhibitors in a clinical setting because it may provide the basis for cerebral edema formation and intracerebral hemorrhage. This would be especially detrimental in combining these inhibitors with radiation therapy, which already leads to transient vessel destabilization per se. Our intravital microscopic studies following SU6668 treatment of orthotopic glioma, however, failed to detect a significant increase in glioma blood vessel permeability. Also we did not observe neurological deterioration in any of our experimental animals following initiation of SU6668 therapy.
Our survival experiments have demonstrated that the potent antiangiogenic, antivascular, and antitumor effects of SU6668 translate into a significant prolongation of survival following intracerebral implantation of C6 malignant glioma cells. Nevertheless, the experiments have also shown that, unfortunately, a monotherapy consisting of SU6668 fails to cure these animals. This may be simply attributable to the aggressive behavior of the C6 malignant glioma. Alternatively, this ultimate treatment failure may be also due to the fact that antiangiogenic therapies do not affect another major hallmark of the pathological characteristics of the glioma, that is, tumor invasion. Instead, it has been recently suggested that antiangiogenic therapies that increase tumor hypoxia may increase glioma cell invasion into surrounding cerebral tissue by activating proinvasive signaling pathways. 8, 18 Unfortunately, the reason for the ultimate escape of our C6 tumors from SU6668 therapy has to remain speculative at the present time because the histological workup of tumor tissue at the time the animals were killed failed to reveal a significant difference between treated and control tumors (data not shown). Nevertheless, the results of this study help define the potential role of antiangiogenic-antivascular therapies in the treatment of malignant glioma in that it is unlikely that these agents will be successful as a monotherapy, but may be of significant value as an adjunct to current multimodality treatments.
Conclusions
In summary, we have shown that SU6668 treatment of orthotopic malignant gliomas potently inhibits tumor angiogenesis, impairs tumor microcirculation, induces regression of existing tumor blood vessels, and, thereby, suppresses tumor growth and prolongs survival. In conclusion, we suggest that targeting multiple angiogenic growth factor receptors with compounds such as SU6668 represents a promising strategy to interfere with the growth and progression of human malignant gliomas. An antiangiogenic-antivascular monotherapy may not be sufficient to control this aggressive tumor entity, however, and thus multimodality therapeutic strategies that combine conventional therapies (resection, radiotherapy, and chemotherapy) with experimental therapies (antiangiogenic-antivascular and antiinvasive treatments) should be considered for use in malignant gliomas in the future.
